Qsemble Capital Management LP Makes New $1.24 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Qsemble Capital Management LP bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,743 shares of the company's stock, valued at approximately $1,238,000.

A number of other large investors also recently modified their holdings of the stock. O Shaughnessy Asset Management LLC lifted its stake in shares of Neurocrine Biosciences by 16.8% during the first quarter. O Shaughnessy Asset Management LLC now owns 3,695 shares of the company's stock valued at $510,000 after acquiring an additional 531 shares during the period. Public Employees Retirement System of Ohio boosted its stake in shares of Neurocrine Biosciences by 6.6% in the 1st quarter. Public Employees Retirement System of Ohio now owns 47,947 shares of the company's stock valued at $6,613,000 after purchasing an additional 2,987 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in shares of Neurocrine Biosciences by 55.4% in the 1st quarter. Kennedy Capital Management LLC now owns 33,236 shares of the company's stock valued at $4,584,000 after purchasing an additional 11,850 shares during the last quarter. Redwood Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences during the 1st quarter worth approximately $642,000. Finally, Motley Fool Asset Management LLC raised its stake in shares of Neurocrine Biosciences by 10.5% during the first quarter. Motley Fool Asset Management LLC now owns 2,067 shares of the company's stock worth $285,000 after buying an additional 197 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded down $1.17 during midday trading on Wednesday, reaching $126.74. The stock had a trading volume of 37,132 shares, compared to its average volume of 873,293. The stock has a market capitalization of $12.83 billion, a P/E ratio of 34.29 and a beta of 0.35. The firm's fifty day simple moving average is $118.83 and its 200-day simple moving average is $131.74. Neurocrine Biosciences, Inc. has a 1-year low of $110.81 and a 1-year high of $157.98.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Robert W. Baird raised their price objective on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the company an "outperform" rating in a research note on Friday, August 2nd. Raymond James restated an "outperform" rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. HC Wainwright reiterated a "buy" rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 1st. Cantor Fitzgerald restated an "overweight" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, Citigroup boosted their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a "neutral" rating in a research report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.